Dose-Reduced Decitabine Might Bring Benefits for Elderly AML Patients with Complex Karyotype: a Case Report

Clin Lab. 2020 Jul 1;66(7). doi: 10.7754/Clin.Lab.2020.191224.

Abstract

Background: Elderly patients with acute leukemia have high mutation frequency and are often accompanied by various underlying diseases, so treatment is difficult and mortality is high.

Methods: We report an elderly acute myeloid leukemia patient with a complex karyotype who received a reduced dose of decitabine in induction chemotherapy due to a combination of severe heart disease.

Results: After a course of induction chemotherapy, the patient achieved complete cytogenetic remission. Cardiac function did not deteriorate during or after chemotherapy.

Conclusions: Dose-reduced decitabine alone can be effective and safe in the induction chemotherapy for elderly AML patients with complex karyotype.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Azacitidine
  • Cytarabine*
  • Decitabine / therapeutic use
  • Humans
  • Karyotype
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Remission Induction
  • Treatment Outcome

Substances

  • Cytarabine
  • Decitabine
  • Azacitidine